The Roboticist Chronicles: Getting Dirty and Dangerous with Abrasive Finishing

 

Robots are perfect for abrasive finishing, because they work well in situations that possess all three of the “Big Ds” – dull, dirty and dangerous.

Even so, while more companies are embracing robotics, there are some areas, like abrasive processing, that are yet to see full integration even though they are “three-D situations.”

“I think it’s kind of interesting that, here we are in the 21st century, and we’re just now starting to robotically automate finishing. Because, if you rewind 60 years ago, one of the first areas we started automating was in machine tools,” said Dan Allford, the president of ARC Specialties. “The difference is, way back then, we were imposing our will on the part. That means we take a big block of metal or whatever and then we machine a part from it.

“Fast forward to now, and you’re trying to do finishing on parts, but we’re having to adapt to the shape of the part. That’s the big difference, and that’s why it’s taken robotics so many years to catch up to machining.”

There’s still work to do, with organizations like ARC and 3M collaborating more and more frequently beyond this special podcast, with 3M co-sponsoring the Robotics Industry Association’s Grinding and Finishing Conference.

“At the end of the day, the knowledge in the industry about robotic abrasive processing is really in its infancy, frankly,” said Scott Barnett, Application Engineering Manager for Robotic Abrasive Processing at 3M. “It is a fairly complex thing to get right, and we want and need industry members to develop more expertise in the space so we can help our customers with their processing challenge.”

Now, after years of slow progress, things are moving quickly in the right direction.

For the latest news, videos, and podcasts in the Engineering & Construction Industry, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

AI in marketing
From Queries to Conversations with AI in Marketing Analytics
April 21, 2025

In this episode of the SparkCast, Aby Varma—founder of Spark Novus, a firm that helps marketing leaders adopt AI responsibly and strategically—sits down with Daniel Kravtsov, CEO and Co-Founder of Improvado. Daniel shares his unique journey from Russia to founding a cutting-edge martech company in the Bay Area. Together, they explore how AI agents…

Read More
ESA
ESA Success Requires Strategy, Infrastructure, and Support Beyond Legislation
April 21, 2025

As education savings accounts (ESAs) gain traction across the United States, the conversation is shifting from policy debates to the complexities of implementation. Fueled by post-pandemic dissatisfaction with traditional school models and a desire for more customizable educational options, ESAs are being adopted in a growing number of states, often under “universal” frameworks. But…

Read More
supply chain data analytics
Supply Chain Data Analytics Fails Without Clean Data, Ventagium Delivers the Fix
April 21, 2025

Supply chain leaders face an overwhelming volume of siloed data across ERPs, TMS platforms, and warehouse systems, yet few know how to align it for smarter decisions. The stakes are rising fast. According to Capgemini’s 2024 report Data: A Powerful Ally in Tackling Scope 3 Emission Reduction Targets, 85% of organizations cite data access…

Read More
cancer immunotherapy
What’s Next in Preclinical Cancer Immunotherapy Research?
April 19, 2025

As the field of cancer immunotherapy rapidly evolves, researchers are turning to next-generation in vitro technologies to replicate the complexities of the tumor microenvironment with unprecedented fidelity. Organoid platforms and ex vivo patient-derived tissue models are transforming how scientists approach preclinical testing, offering deeper mechanistic insights and better predictive power for therapeutic response. With immunotherapies…

Read More